AYTU - Aytu BioScience, Inc.
| Previous Close | 1.2100 |
| Open | 1.2500 |
| Bid | 1.1800 x 900 |
| Ask | 1.2300 x 1200 |
| Day's Range | 1.1500 - 1.2700 |
| 52 Week Range | 0.6800 - 2.6100 |
| Volume | 37,797 |
| Avg. Volume | 137,326 |
| Market Cap | 21.403M |
| Beta (3Y Monthly) | 4.80 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.4810 |
| Earnings Date | Nov 5, 2019 - Nov 11, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.38 |
- ACCESSWIRE
Aytu BioScience Acquires $12.4 Million Prescription Product Portfolio
ENGLEWOOD, CO / ACCESSWIRE / October 14, 2019 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced the signing of an asset purchase agreement to acquire a portfolio of prescription products from Cerecor, Inc. (the "Commercial Portfolio"). The Commercial Portfolio and accompanying commercial infrastructure generated $12.4 million in net revenue and was profitable on a standalone basis for the twelve months ending June 30, 2019.
- ACCESSWIRE
Aytu BioScience Announces $10 Million Private Placement
ENGLEWOOD, CO / ACCESSWIRE / October 14, 2019 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, is pleased to announce that it has entered into definitive agreements with two institutional investors for the purchase and sale in a private placement of $10 Million of Series F Convertible Preferred Stock and warrants to purchase common stock. Institutional investors Altium Capital and Armistice Capital jointly participated in the financing.
- ACCESSWIRE
Aytu BioScience and Validus Pharmaceuticals Announce ZolpiMist Co-Promotion Agreement and Launch Into the $163 Million Psychiatry Market
Co-Promotion Expands Physician Promotion of Aytu's Prescription Sleep Aid with Dedicated Specialty Sales Force, into Psychiatry Market, Which Accounted for Over 2.7 Million Zolpidem Tartrate Prescriptions ...
- ACCESSWIRE
Aytu BioScience Reports 100% Revenue Growth to $7.3 million in FY 2019
Results Do Not Include September 2019 Definitive Agreement to Acquire Innovus Pharmaceuticals: Combined LTM revenues of over $31M, Diversifies product line by 10x to over 30 products ENGLEWOOD, CO / ACCESSWIRE ...
- ACCESSWIRE
Aytu BioScience Announces Addition of Natesto(R) to Leading National Pharmacy Benefit Manager’s Formulary; Natesto Added to Commercial Plans Covering Over 30 Million U.S. Lives
During the 12-month period ending June 2019, the U.S. prescription TRT market registered 6.9 million prescriptions, generating approximately $1.7 billion in revenue ENGLEWOOD, CO / ACCESSWIRE / September ...
- ACCESSWIRE
Aytu BioScience to Report Fiscal FY 2019 Results and Business Update
ENGLEWOOD, CO / ACCESSWIRE / September 19, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, ...
- ACCESSWIRE
Aytu BioScience to Present at Ladenburg Thalmann 2019 Healthcare Conference
ENGLEWOOD, CO / ACCESSWIRE / September 17, 2019 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that Josh Disbrow, Chairman and Chief Executive Officer, and David Green, Chief Financial Officer, will present at the Ladenburg Thalmann 2019 Healthcare Conference at 10:00 a.m. ET on Tuesday, September 24, 2019 at the Sofitel NYC. Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on commercializing novel products that address significant patient needs. Aytu also has exclusive U.S. and Canadian rights to ZolpiMist™, an FDA-approved, commercial-stage prescription sleep aid indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation.
- ACCESSWIRE
Aytu BioScience Announces Definitive Agreement to Acquire Innovus Pharmaceuticals
ENGLEWOOD, CO and SAN DIEGO, CA / ACCESSWIRE / September 12, 2019 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs and Innovus Pharmaceuticals, Inc. (INNV), a specialty pharmaceutical company commercializing, licensing and developing safe and effective consumer health products, today announced that the companies have signed a definitive merger agreement whereby Aytu will retire all outstanding common stock of Innovus for an aggregate of up to $8 million in shares of Aytu common stock, less certain deductions, at the time of closing. This initial consideration to Innovus common shareholders is estimated to consist of approximately 4.2 million shares of Aytu stock.
- ACCESSWIRE
Aytu BioScience Announces Availability of the MiOXSYS(R) Male Infertility Test in South Africa
ENGLEWOOD, CO / ACCESSWIRE / September 10, 2019 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced that MiOXSYS®, the company’s first-in-class seminal oxidative stress test for the assessment of male infertility, is now available in South Africa and is offered through Androcryos, the largest sperm bank on the African continent. MiOXSYS, the Male Infertility Oxidative System, is CE marked and cleared by Health Canada, Australia's TGA, and Mexico's COFEPRIS.
- Simply Wall St.
Do Insiders Own Lots Of Shares In Aytu BioScience, Inc. (NASDAQ:AYTU)?
A look at the shareholders of Aytu BioScience, Inc. (NASDAQ:AYTU) can tell us which group is most powerful. Insiders...
- ACCESSWIRE
Aytu BioScience Announces Tuzistra XR Co-Promotion Agreement with Poly Pharmaceuticals
Co-promotion nearly doubles Tuzistra XR sales force Poly’s geographic footprint covers approximately 750,000 antitussive prescriptions annually accounting for approximately $128 million in annual revenue ...
- Zacks
What's in Store for Aytu BioScience's (AYTU) Q4 Earnings?
On Aytu BioScience's (AYTU) upcoming earnings call, investor focus will be on its diversified portfolio of medicines approved to treat ailments like low testosterone, insomnia and male infertility.
- ACCESSWIRE
Aytu BioScience Announces First ZolpiMist(TM) Clinical Study Results Demonstrating More Rapid Sleep Onset with Lingual Spray Zolpidem versus Oral Tablet
ENGLEWOOD, CO / ACCESSWIRE / August 5, 2019 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today the publication of a clinical study in the journal Pharmacy and Pharmacology, demonstrating that ZolpiMist, Aytu BioScience’s lingual spray formulation of zolpidem, achieves sleep onset more quickly than the oral tablet form of zolpidem (brand name Ambien®) in patients seeking short-term treatment for insomnia. This new scientific report describes a post-hoc analysis of data from the pivotal Phase 3 study of ZolpiMist.
- Zacks
Is Aytu Bioscience (AYTU) Outperforming Other Medical Stocks This Year?
Is (AYTU) Outperforming Other Medical Stocks This Year?
- ACCESSWIRE
Natesto Spermatogenesis Study Final Results Accepted for Presentation at 'Late-Breaking' Session at the American Society for Reproductive Medicine 75th Annual Scientific Conference
ENGLEWOOD, CO / ACCESSWIRE / August 1, 2019 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that the Natesto Spermatogenesis Study results have been accepted for presentation as a “Late-Breaking Abstract” by the American Society for Reproductive Medicine (ASRM). The study results will be presented at the 75th ASRM Scientific Congress & Expo in Philadelphia, PA October 12-16, 2019.
- PR Newswire
Acerus And Aytu Bioscience To Co-Promote NATESTO® In The United States
TORONTO, July 30, 2019 /PRNewswire/ -- Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB: ASPCF) today announced that it will be taking an expanded role in the commercialization of NATESTO® in the U.S. The company has entered into an amended and restated licensing agreement with Aytu BioScience, Inc. (AYTU), which will, upon closing, move the partnership from an out-license model to a co-promotion arrangement that the companies believe will leverage their collective product, marketplace and Men's Health experience to capture a significant share of the U.S. market for NATESTO®. Under the terms of the new agreement, Aytu returns the NDA for NATESTO® in the U.S. back to Acerus. Going forward Acerus will assume all regulatory and clinical responsibilities and costs for the product in the U.S. Acerus will take on a more expansive role in matters such as U.S. marketing, reimbursement and medical strategy as part of the companies' joint commercialization committee, and will launch a specialist sales force focused on urologists and endocrinologists (Acerus Sales Channel).
- ACCESSWIRE
Aytu BioScience Expands Natesto(R) Partnership with Acerus Pharmaceuticals to Accelerate Natesto Growth in the U.S.
ENGLEWOOD, CO / ACCESSWIRE / July 30, 2019 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced the expansion of the company’s partnership with Acerus Pharmaceuticals (“Acerus”) to accelerate the growth of Natesto® in the United States. Through this expanded commercial relationship, Acerus will fund and launch a U.S.-based specialty sales force which will promote Natesto to urologists and endocrinologists.
- ACCESSWIRE
Natesto(R) Added to National Pharmacy Benefit Manager's Formulary Natesto Now Covered on Payer Plans Covering Over 6 Million U.S. Lives
ENGLEWOOD, CO / ACCESSWIRE / July 24, 2019 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced that Natesto® (testosterone nasal gel) is now on formulary and covered nationwide by a leading national pharmacy benefit manager (PBM). This PBM contract provides for unrestricted patient access to Natesto across the PBM’s national open formularies and plans that service government clients. Over six million U.S. lives are covered by these prescription plans.
- Zacks
The Zacks Analyst Blog Highlights: Middlesex Water, Howard Hughes, Ubiquiti, Aptose and Aytu
The Zacks Analyst Blog Highlights: Middlesex Water, Howard Hughes, Ubiquiti, Aptose and Aytu
- Zacks
Sarepta Stock Up Almost 40% This Year So Far: Here's Why
Sarepta's (SRPT) key product, Exondys 51, continues to perform well. Its lead pipeline candidate, golodirsen, is nearing approval. The company is also developing gene therapies.
- Benzinga
Aytu BioScience Shares Clinical Results For Natesto Testosterone Medication
Aytu BioScience (NASDAQ: AYTU ) announced the publication of clinical study results demonstrating the effectiveness of Natesto regardless of patients' baseline Hypogonadism severity. Natesto Testosterone ...
- ACCESSWIRE
Aytu BioScience Announces Publication of Clinical Study Results Demonstrating Effectiveness of Natesto(R) Regardless of Patients’ Baseline Hypogonadism Severity
ENGLEWOOD, CO / ACCESSWIRE / July 8, 2019 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today the acceptance of a new manuscript submitted to the Journal of the Endocrine Society, demonstrating that Natesto® achieves similar symptom improvement, regardless of the degree of patients’ testosterone deficiency, while maintaining function of the Hypothalamic-Pituitary-Gonadal (HPG) axis in hypogonadal men. Josh Disbrow, Chief Executive Officer of Aytu BioScience, commented, “With the publication of this study, entitled Efficacy of Nasal Testosterone Gel (Natesto) Stratified by Baseline Endogenous Testosterone Levels, we now have clear evidence that Natesto is effective for a wide range of hypogonadal patients regardless of the degree of their baseline hypogonadism.
- Zacks
Bond Yields Plunge Globally on Slowdown Fears: 5 Safe Picks
A growing number of central banks are giving signals for pursuing easy monetary policy in order to raise inflation and generate economic growth.
- ACCESSWIRE
Aytu BioScience Added to Russell Microcap(R) Index
ENGLEWOOD, CO / ACCESSWIRE / July 1, 2019 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced that it has been added to the Russell Microcap® Index effective after the U.S. markets open today, July 1, 2019. Membership in the Russell Microcap® Index, which remains in place for one year, means the automatic inclusion of Aytu BioScience's common stock in the appropriate growth and value index funds designed to track stocks included in the Russell Microcap® Index. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.
